Penumbra stock reports 14.9 percent revenue growth as EPS misses

Published on 10/05/2026 at 22:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Penumbra stock stood at USD 317.74 on October 2, 2026, while Q2 revenue reached USD 390.05 million. Analysts set a USD 367.07 average target across 17 firms.

PEN, US70975L1070, Illustration mit AI erstellt.

Penumbra stock (ISIN US70975L1070) was last at USD 317.74 on the NYSE on October 2, 2026, up 0.06 percent from the prior close. The latest quarterly figures show a sharp split between revenue growth and earnings execution, with second-quarter 2026 revenue up 14.9 percent year over year.

Revenue grows while EPS misses

According to MarketBeat on September 14, 2026, Penumbra reported USD 390.05 million in second-quarter revenue, compared with a USD 389.64 million consensus estimate. Revenue therefore exceeded expectations by USD 0.41 million while also rising 14.9 percent from the year-earlier quarter.

The earnings side was weaker. Diluted EPS came in at USD 0.88 for the quarter ended June 30, 2026, below the USD 1.16 consensus estimate by USD 0.28, even though the prior-year figure was USD 0.86. For investors, the central issue is whether double-digit sales growth can translate into stronger earnings conversion.

Hold consensus leaves upside gap

MarketBeat lists a consensus Hold rating from 17 analysts, including 14 Hold ratings and three Buy ratings. The average 12-month price target is USD 367.07, with a high target of USD 388.00 and a low target of USD 320.00.

Against the October 2 NYSE price of USD 317.74, the average target lies 15.5 percent above the price. The low target is only USD 2.26 above the reference price, which shows how closely the lower end of analyst expectations sits to the latest market level.

Valuation stays elevated

Penumbra's market capitalization stood at USD 12.5 billion on October 2, 2026, while trading volume was 239,678 shares. The same session's 52-week range ran from USD 221.26 to USD 362.41, placing the stock USD 44.67 below its yearly high.

Penumbra develops medical devices for neurovascular and vascular conditions, including technologies used in minimally invasive procedures. The company says its products support healthcare providers, hospitals and clinics in more than 100 countries, giving the revenue trend a broad commercial base while the EPS miss keeps profitability central to the next results cycle.